SEASTAR MEDICAL HOLDING CORP

ICUNASDAQ

🏆 #3635 by market capEarnings Aug 12 · PostUS Equity

$162.69▲ $7.96 (+4.89%)

Simulated price

1h—

24h▲ 4.9%

7d—

14d—

30d—

1y—

🏦Market Cap

$15M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

93.1%

High

💵FCF Margin

—

⚖️P/S Ratio

10.3x

Elevated

Otter Score

Fair

No chart data available for ICU.

Trading Snapshot

Day Range: $160.69 – $163.67
52-Week Range: $2.07 – $12.50
Volume: $3.08B
Avg Volume: $3.07B
Shares Outstanding: 4.0M
Next Earnings: Oct 2, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $495,000
P/E Ratio: —
P/S Ratio: 10.3x
EPS (TTM): $-4.78
Dividend Yield: —

Why Investors Own ICU

✓High-growth profile — revenue up +50.5% YoY with expanding US Equity exposure.
✓Healthy economics — 59% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$1M▲ +44.6% YoY

Gross Margin (TTM)

58.9%▼ −0.2% YoY

Operating Income (TTM)

$235,694▲ +44.6% YoY

Free Cash Flow (TTM)

$75,274▲ +44.6% YoY

About SEASTAR MEDICAL HOLDING CORP

SeaStar Medical Holding Corporation is a medical device company dedicated to providing innovative solutions and services designed to combat hyperinflammation and cytokine storm in critically ill individuals. The company specializes in developing and commercializing extracorporeal therapies that specifically target the immune 'effector cells' responsible for driving systemic inflammation, a process that directly harms tissues and releases a cascade of pro-inflammatory cytokines, thereby initiating and perpetuating dysregulated immune reactions. Its product pipeline spans various critical care areas, including acute kidney injury (both pediatric and adult) requiring continuous renal replacement therapy (CRRT), cardiorenal syndrome in patients with congestive heart failure (including those with or without LVADs), myocardial stunning in end-stage renal disease, and hepatorenal syndrome. The firm maintains its headquarters in Denver, Colorado.

🦦